Although these are indeed very limited studies using one type of cancer, the three animal studies performed to date, using mAbs targeting different regions of gC1qR, should mitigate the legitimate concern that such a ubiquitously expressed molecule could be targeted for therapy without consequential side effects (1, 44). This evidence concerns the gene C1QBP and cancer.